tiprankstipranks
Trending News
More News >

Health Catalyst price target lowered to $9 from $10 at Canaccord

Canaccord lowered the firm’s price target on Health Catalyst (HCAT) to $9 from $10 and keeps a Buy rating on the shares. The firm said while they are lowering their 2Q estimates, their 2025 forecasts are only modestly tweaked. Clearly, there remains uncertainty given the macro environment, but managementindicated confidence in a growing pipeline of new business opportunities to reach its bookings target.

Confident Investing Starts Here:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Disclaimer & Disclosure

Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.

Report an Issue